NVAX · Novavax Inc
United States · RS rating 72 · As of 2026-11-03
| Price | 9.68 USD |
|---|---|
| 1-day change | +1.6% |
| RS rating (overall / 1M / 3M / 12M) | 72 / 19 / 91 / 64 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 48 / 61 / 53 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +108.8% |
| Sales growth Q/Q | +108.9% |
| Distance from 52-week high | +24.5% |
| Market cap (USD) | $1.3B |